8-hydroxy-2-(di-n-propylamino)tetralin has been researched along with Parkinson Disease in 15 studies
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.
8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that hyperalgesia of 6-OHDA rats may be related to increased excitability of SDH neurons, and functional change of 5-HT3 receptor may reverse the hyperalgesia of 6-OHDA lesioned rats and decrease cell excitability of SDH neurons." | 1.72 | Inhibition of Spinal 5-HT3 Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinson's Disease. ( An, MQ; Dai, YP; Dong, LG; Gu, HY; Li, CJ; Liu, CF; Liu, LB; Mao, CJ; Wang, F; Zhang, LG, 2022) |
| "Depression is one of the most common neuropsychiatric disturbances in Parkinson's disease (PD), but its pathophysiology is not definite." | 1.56 | Involvement of the Dorsal Hippocampus 5-HT1A Receptors in the Regulation of Depressive-Like Behaviors in Hemiparkinsonian Rats. ( Guo, Y; Hu, W; Jiang, YF; La, XM; Liu, J; Wang, HS; Xie, W; Yang, J; Zhang, J; Zhang, L, 2020) |
| "The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile." | 1.42 | Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. ( Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N, 2015) |
| "Motor symptoms of Parkinson's disease are commonly treated using l-DOPA although long-term treatment usually causes debilitating motor side effects including dyskinesias." | 1.39 | Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease. ( Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Goldenberg, AA; Lindenbach, D; Ostock, CY, 2013) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, CJ | 1 |
| Zhang, LG | 1 |
| Liu, LB | 1 |
| An, MQ | 1 |
| Dong, LG | 1 |
| Gu, HY | 1 |
| Dai, YP | 1 |
| Wang, F | 1 |
| Mao, CJ | 1 |
| Liu, CF | 1 |
| Liu, Y | 1 |
| Liu, J | 3 |
| Jiao, SR | 1 |
| Liu, X | 1 |
| Guo, Y | 2 |
| Zhang, J | 2 |
| Yang, J | 2 |
| Xie, W | 2 |
| Wang, HS | 2 |
| Zhang, L | 2 |
| Jiang, YF | 1 |
| Hu, W | 1 |
| La, XM | 1 |
| Miyazaki, I | 1 |
| Asanuma, M | 1 |
| Murakami, S | 1 |
| Takeshima, M | 1 |
| Torigoe, N | 1 |
| Kitamura, Y | 1 |
| Miyoshi, K | 1 |
| Lindenbach, D | 2 |
| Dupre, KB | 2 |
| Eskow Jaunarajs, KL | 1 |
| Ostock, CY | 2 |
| Goldenberg, AA | 1 |
| Bishop, C | 3 |
| Hui, YP | 1 |
| Wang, T | 1 |
| Han, LN | 1 |
| Li, LB | 1 |
| Sun, YN | 1 |
| Qiao, HF | 1 |
| Zhang, QJ | 1 |
| Palumbo, N | 1 |
| Vilceus, N | 1 |
| Conti, MM | 1 |
| Eskow, KL | 1 |
| Barnum, CJ | 1 |
| Sharp, SI | 1 |
| Ballard, CG | 1 |
| Ziabreva, I | 1 |
| Piggott, MA | 1 |
| Perry, RH | 1 |
| Perry, EK | 1 |
| Aarsland, D | 1 |
| Ehrt, U | 1 |
| Larsen, JP | 1 |
| Francis, PT | 2 |
| Muñoz, A | 1 |
| Li, Q | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 1 |
| Carlsson, T | 1 |
| Kirik, D | 1 |
| Di Luca, M | 1 |
| Björklund, A | 1 |
| Bezard, E | 1 |
| Carta, M | 1 |
| Nahimi, A | 1 |
| Høltzermann, M | 1 |
| Landau, AM | 1 |
| Simonsen, M | 1 |
| Jakobsen, S | 1 |
| Alstrup, AK | 1 |
| Vang, K | 1 |
| Møller, A | 1 |
| Wegener, G | 1 |
| Gjedde, A | 1 |
| Doudet, DJ | 1 |
| Mignon, LJ | 1 |
| Wolf, WA | 2 |
| Tomiyama, M | 1 |
| Kimura, T | 1 |
| Maeda, T | 1 |
| Kannari, K | 1 |
| Matsunaga, M | 1 |
| Baba, M | 1 |
| Mignon, L | 1 |
| Chen, CP | 1 |
| Alder, JT | 1 |
| Bray, L | 1 |
| Kingsbury, AE | 1 |
| Foster, OJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 other studies available for 8-hydroxy-2-(di-n-propylamino)tetralin and Parkinson Disease
| Article | Year |
|---|---|
Inhibition of Spinal 5-HT3 Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinson's Disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dopamine; Hyperalgesia; Ondansetron; Oxidopamine; P | 2022 |
Serotonin
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Dopamine; Habituation, Psyc | 2019 |
Involvement of the Dorsal Hippocampus 5-HT1A Receptors in the Regulation of Depressive-Like Behaviors in Hemiparkinsonian Rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Behavior, Animal; Depression; Disease Mod | 2020 |
Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Astrocytes; Brain; Buspirone; Ce | 2013 |
Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Extracellu | 2013 |
Anxiolytic effects of prelimbic 5-HT(1A) receptor activation in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Anima | 2015 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskin | 2015 |
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine | 2008 |
Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aged; Aged, 80 and over; Antidepressive Agents; Antiparkinso | 2008 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autorad | 2012 |
8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Aspartic Acid; Corpus Striatum; Denervation; Diseas | 2005 |
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Stri | 2005 |
Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Brain Chemi | 2007 |
Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Humans; Ketanserin; Kinetics; Neocortex; Parkinson Disease; | 1998 |